151 related articles for article (PubMed ID: 9236571)
21. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
Chatellier G; Lacomblez L
BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
[TBL] [Abstract][Full Text] [Related]
22. WITHDRAWN: Tacrine for Alzheimer's disease.
Qizilbash N; Birks J; Lopez Arrieta J; Lewington S; Szeto S
Cochrane Database Syst Rev; 2007 Jul; (3):CD000202. PubMed ID: 17636619
[TBL] [Abstract][Full Text] [Related]
23. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group.
Knopman D; Schneider L; Davis K; Talwalker S; Smith F; Hoover T; Gracon S
Neurology; 1996 Jul; 47(1):166-77. PubMed ID: 8710072
[TBL] [Abstract][Full Text] [Related]
24. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
Zemlan FP
J Neural Transm (Vienna); 1996; 103(8-9):1105-16. PubMed ID: 9013398
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of tacrine hydrochloride (Cognex) in two parallel-group studies.
Gracon SI
Acta Neurol Scand Suppl; 1996; 165():114-22. PubMed ID: 8740998
[TBL] [Abstract][Full Text] [Related]
26. Characteristic deterioration of ADAS-Jcog subscale scores and correlations with regional cerebral blood flow reductions in Alzheimer's disease.
Yoshii F; Kawaguchi C; Kohara S; Shimizu M; Onaka H; Ryo M; Takahashi W
Neurol Sci; 2018 May; 39(5):909-918. PubMed ID: 29508099
[TBL] [Abstract][Full Text] [Related]
27. Response patterns of EGb 761 in Alzheimer's disease: influence of neuropsychological profiles.
Le Bars PL
Pharmacopsychiatry; 2003 Jun; 36 Suppl 1():S50-5. PubMed ID: 13130389
[TBL] [Abstract][Full Text] [Related]
28. State, trait, and accumulated features of the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) in mild Alzheimer's disease.
Cogo-Moreira H; Krance SH; Wu CY; Lanctôt KL; Herrmann N; Black SE; MacIntosh BJ; Rabin JS; Eid M; Swardfager W;
Alzheimers Dement (N Y); 2023; 9(1):e12376. PubMed ID: 36994227
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
Antuono PG
Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
[TBL] [Abstract][Full Text] [Related]
30. Acetylcholinesterase inhibition in dementia with Lewy bodies: results of a prospective pilot trial.
Querfurth HW; Allam GJ; Geffroy MA; Schiff HB; Kaplan RF
Dement Geriatr Cogn Disord; 2000; 11(6):314-21. PubMed ID: 11044776
[TBL] [Abstract][Full Text] [Related]
31. Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items.
Schmitt FA; Aarsland D; Brønnick KS; Meng X; Tekin S; Olin JT
Am J Alzheimers Dis Other Demen; 2010 Aug; 25(5):407-13. PubMed ID: 20392860
[TBL] [Abstract][Full Text] [Related]
32. Potential role for estrogen replacement in the treatment of Alzheimer's dementia.
Schneider LS; Farlow MR; Pogoda JM
Am J Med; 1997 Sep; 103(3A):46S-50S. PubMed ID: 9344406
[TBL] [Abstract][Full Text] [Related]
33. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial.
Maltby N; Broe GA; Creasey H; Jorm AF; Christensen H; Brooks WS
BMJ; 1994 Apr; 308(6933):879-83. PubMed ID: 8173365
[TBL] [Abstract][Full Text] [Related]
35. A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease.
Weyer G; Babej-Dölle RM; Hadler D; Hofmann S; Herrmann WM
Neuropsychobiology; 1997; 36(2):73-82. PubMed ID: 9267856
[TBL] [Abstract][Full Text] [Related]
36. An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. The Tacrine 970-6 Study Group.
Foster NL; Petersen RC; Gracon SI; Lewis K
Dementia; 1996; 7(5):260-6. PubMed ID: 8872417
[TBL] [Abstract][Full Text] [Related]
37. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease.
Farlow MR; Lahiri DK; Poirier J; Davignon J; Schneider L; Hui SL
Neurology; 1998 Mar; 50(3):669-77. PubMed ID: 9521254
[TBL] [Abstract][Full Text] [Related]
38. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study.
Kaufer DI; Cummings JL; Christine D
J Geriatr Psychiatry Neurol; 1996 Jan; 9(1):1-6. PubMed ID: 8679057
[TBL] [Abstract][Full Text] [Related]
39. Alzheimer Disease Assessment Scale: a subtest analysis.
Zec RF; Landreth ES; Vicari SK; Belman J; Feldman E; Andrise A; Robbs R; Becker R; Kumar V
Alzheimer Dis Assoc Disord; 1992; 6(3):164-81. PubMed ID: 1485931
[TBL] [Abstract][Full Text] [Related]
40. Assessing individual patients for cognitive benefits from acetylcholinesterase inhibitors.
Sands LP; Katz I; Schneider L
Alzheimer Dis Assoc Disord; 1999 Jan; 13(1):26-33. PubMed ID: 10192639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
